VenoVision selected for the Health Wildcatters 2022 Accelerator to Improve Patient Monitoring

From the Hebrew University's bench to bedsides in Dallas, TX, VenoVision brings cardiological expertise to non-invasive hemodynamic remote patient monitoring.

Online PR News – 12-September-2022 – Dallas, Texas – VenoVision was selected as one of only 11 start-ups from hundreds to participate in the Health Wildcatters 2022 Program.

VenoVision will help improve therapeutic management, patient outcomes, and drive down the billions of dollars wasted every year on preventable perioperative deterioration and rehospitalization of those suffering, or at risk of, heart failure and other hemodynamic complications.

VenoVision CSO, Prof. Yaakov Nahmias, said, “Our mission is to set a new frontier in contactless hemodynamic monitoring and accelerate the disruptive shift from conventional intervention techniques towards objective, non-invasive and continuous monitoring. Our ‘point-and-press’ novel technology enables a whole new market of advanced low-cost monitoring for chronic patients living a life of misery without a real cure available.”
Prof. Nahmias continued, “No matter the cardiological expertise available, we want to deliver the insights previously limited to invasive catheterization to all environments. We will support medical teams to stabilize patients, specifically overcoming the challenges of non-invasively monitoring obese or overweight cardiovascular patients.”

“We are very excited to work with our 5th Israeli team at Health Wildcatters, signifying the close ties and our great regard for Israeli innovation”, said Hubert Zajicek, MD, CEO & Co-founder of Health Wildcatters. “Cardiac care is still one
of THE top goals for any doctor and we are confident that Venovision will play an important role in improving patients lives”, he said.

VenoVision was conceptualized in The Hebrew University’s BioDesign program, a multidisciplinary, team-based approach to medical innovation under the supervision of Prof. Yaakov Nahmias, Ph.D., Prof. Dan Galai, Ph.D., and Prof. Dr. Tal Hasin, MD. Since then, it has completed a proof-of-concept clinical trial at Shaare Zedek Medical Center, Jerusalem, been granted its first patent in February 2022, and was a MassChallenge Israel Finalist.

On joining the Health Wildcatters 2022 program, VenoVision CEO, Jonathan Maron, said, “We are delighted to enter the extensive, open and innovative medical ecosystem of Texas as we launch our medtech venture.”

With seed investment, mentorship and a tailored program, VenoVision will be working with Health Wildcatters to establish the core partnerships to initiate its milestone-based commercialization plan across product development, clinical and regulatory pathways.


About VenoVision
VenoVision will help improve therapeutic management, patient outcomes, and drive down the billions of dollars wasted on preventable deterioration and rehospitalization by supporting medical teams to non-invasively monitor and stabilize the hemodynamics of those suffering, or at risk of, heart failure and related complications. VenoVision is a low-cost, easy-to-use, contactless, deep-thermal imaging device and hemodynamic monitoring platform for the inpatient, outpatient and home environments.

About Health Wildcatters
Health Wildcatters is the top healthcare seed accelerator in the Southwest. It is a physician-led, mentorship driven, seed investment, 12-week program, and is designed to support its start-ups overcome the unique challenges of the healthcare industry.